1Hardingham T. Extracellular matrix and pathogenic mechanisms in osteoarthritis Curr Rheumatol Rep. 2008; 10(1):3036.
2Watanabe H. Aggrecan and its chondroitin sulfate in cartilage. Seikagaku, 2008; 80(1):28-32.
3Sandy JD, Neame PJ, Boynton RE, et al. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem, 1991 ; 266(14) :8683-8685.
4Blaney-David,mn EN, Vitters EL, van Lent PI,. et al. Elevated extracellular nkatrix production and degradation upon bone morphogenetic protein-2 (BMP 9) stimulation point toward a role for BMP2 in cartilage repair and remodeling. Arthritis Res fher. 2007. 9(5):RI02.
5Gendron C, Kashiwagi M, l.im NH, et al. Proteolytic activitics of human .ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem, 2007; 282(25): 18294-18306.
6Zeng W. Corcoran C, Collins-Rade I.,A. et al. Glycosaminoglycarrbincling prcr perties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMIS-5, -9, -16 and -18. Biochim Biophys.Acta. 2006. 1760(3):517-524.
7Stevens M., Wheeler CA, Tannenbaum SR. et al. Nitric oxide enhances aggrecan degradation by aggrecana~ in reaponse to TNF-alpha but not IL-lbeta treat ment at a post-transcriptional level in bovine cartilage explants. Osteoarthritis Cartilage, 2008. 16(4):489-497.
8Karsdal MA, Surfer EU. Wulf H. et al. Induction of increased cAMP levds in art cular chondrocytes blocks mAtrix metalloprote nase-mediated cartilage degradation, but not aggrecanasesn-mediated cartilage degradation. Arthritis Rheum, 2007; 56(5):1549-1558.
9Shao X, Hunter CJ. Developing an alginate/chitosan hybrid fiber .scaffold for annulus fihrosus cells. J Biomed Mater Res A, 2007; 82(3):701-710.
10Laroazares M. Obaya AJ, Moncada-Pazos A. et al. The ADAMTS12 metalloproteinase exhibits anti-t urrlorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci. 2007; 120(Pt 20):3544-3552.
2Buckwalter JA, Nankin HJ,Qodzinslty AJ. Articular cartilage and osteoarthritis[J].Instr Course Lect, 2005, 54:465-480.
3Poole AR,Kobayashi M,Yasuda T, et al. Type Ⅱ collagen degradation and its regulation in articular cartilage in osteoarthritis [J]. Ann Rheum Dis, 2002, 61(Suppl 2) :ii78-ii81.
4Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation [J].Arthritis Res Ther, 2003 , 5(2):94-103.
5Cbnaghan PG. Osteoarthritis in 2012: Parallel evolution of OA phenotypes and therapies[J]. Nat Rev Rheumatol, 2013, 9(2):68-70.
6van der Kraan PM,Blaney-Davidson EN, van den Berg WB. Bone morphogenetic protans and articular cartilage: to serve and protect or a vrolf in sheep dothing's?[J]. Osteoarthritis Cartilage,2010, 18(6) :735-741.
7Hayashi M,Mjneta T, Takahashi T, et al. Intra-articular injections of bone morphogenetic protein-7 retard progresaon of existing cartilage degeneration[J]. J Qrthop Res,2010, 28(11):1502-1506.
8Hayashi M, Muneta T, Ju YJ, et al. Weekly intra-articular injections of bone rnorphcgenetic protein-7 inhibits osteoarthritis progresaon[J]. Arthritis Res Ther,2008,10(5):R118.
9Fosang AJ,Little CH Drug insight: aggrecanases as therapeutic targets for osteoarthritis[J]. Nat Qin Pract Rheumatol, 2008,4(8):420-427.
10Reboul P,Pelletier JP, Tardif G, et al. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis[J]. J Qin Invest, 1996, 97(9) :2011-2019.
